Brief: Initiator Pharma Reports Dose-Dependent Significant Efficacy Of Ip2018

Initiator Pharma A/S

05/06/2023 06:37

June 5 (Reuters) - Initiator Pharma A/S  INIT.ST :
    * REPORTS DOSE-DEPENDENT SIGNIFICANT EFFICACY OF IP2018 IN
THE
PLACEBO-CONTROLLED PHASE IIA CLINICAL TRIAL OF ERECTILE
DYSFUNCTION
    * NO OBSERVATIONS OF SERIOUS OR CRITICAL ADVERSE EVENTS IN
PHASE
IIA CLINICAL TRIAL OF IP2018 IN PATIENTS WITH MILD TO MODERATE
ED
    * EFFECT OF IP2018 ON ERECTILE FUNCTION WAS DOSE-DEPENDENT
    * NO SAFETY OBSERVATIONS OF CONCERN HAVE BEEN REPORTED

Source text for Eikon:  ID:nMFN7WVPpd 
Further company coverage:  INIT.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))